PDX INSIGHTS
PIONEERING CANCER RESEARCH
Model Details

Patient Information for Model: TCCC-OS51


Patient Information
Model: TCCC-OS51
Gender: Female
Race/Ethnicity: White
Vital Status: Deceased
Initial Diagnosis: Osteosarcoma|Osteoblastic
Age at Diagnosis: 8
Bone Sarcoma Stage: Metastatic
Primary Site: Right tibia
Metastasis Sites: Bone
Clinical Timeline


Clinical Information at Collection
Collection Age: 8.00
Collection Procedure: Biopsy
Survival in months: 22
Time of Specimen Collection: Diagnosis
Clinical Biomarkers/Mutations
Germline TP53: Not Performed
Rhabdo Clinical Group: Not Reported
Cytogenetics: 46,XX,t(2;7)(q37;q31)[3]/46,XX[17]
Clinical Mutation Panel: Not Reported
Pathology Information at Collection
Histologic Response: Not Reported
Treatment Naive: Yes
Histology Subtypes: Osteoblastic

Model Information for Model: TCCC-OS51

Model Details - Initial Implantation of Patient Tissue
Host Strain: NSG
Transplant Specimen Condition:
Transplant Material: Tissue Fragment
Transplant Supplements: None
Transplant Site: Subcutaneous, flank tumor implantation
Humanization: None
RECOL4: Not Reported
Specimen Site: Right tibia
Mutations (Cancer Gene Census List)
Mutation data is currently not available.

CNV
There are no omics data for this model.


Histology Information for Model: TCCC-OS51
There are no histology images for this model.













Metastasis Information for Model: TCCC-OS51
 
Patient
PDX
Bone
Lung

Patient Treatment Information for Model: TCCC-OS51

Event IdTreatmentTreatment SettingAge at StartAge at EndDurationClinical ResponsePathologic ResponseReason Stopped
10Methotrexate, Doxorubicin, CisplatinNeoadjuvant8.08.2591 daysPartial ResponsePoor response (75% tumor necrosis, tibia; 20% tumor necrosis L3)Surgical resection (local control & metastectomy)
20Methotrexate, Doxorubicin, CisplatinAdjuvant8.258.66150 daysNo evidence of diseaseEnd of therapy
35Ifosfamide /EtoposideAdjuvant9.089.2562 daysNo evidence of diseaseEnd of therapy